| 
                
               | 
               
            
              
  | 
               
            
              
     
 | 
              
 
US, China working on vaccine against coronavirus: Expert
 | 
             
            
              
  | 
               
           
            
              
                
                  
                    
                      
 
                       | 
                     
                    
                       | 
                     
                    
                      
               
                
                   
                    
                      
                        |    Top Stories  | 
                          | 
                       
                      | 
                   
                  
                     | 
                   
                                 
                       | 
                     
                   
                  
                  IANS | 23 Jan, 2020 
                  US and Chinese medical institutions are working together to develop a 
vaccine against the novel coronavirus (2019-nCoV) which has already 
caused 440 confirmed cases of pneumonia in China, a US vaccine scientist
 said on Wednesday.
  Peter Hotez, professor and dean of the 
National School of Tropical Medicine at Baylor College of Medicine (BCM)
 in Houston, Texas, said his group at the Texas Children's Hospital 
Center for Vaccine Development at BCM is working to develop a vaccine in
 collaboration with other US institutions such as the University of 
Texas Medical Branch, and the New York Blood Center, and with the 
Virology Center at Fudan University in Shanghai, China.
  "This is a
 great collaboration," Hotez told the Xinhua news agency. "But vaccine 
development is not a fast process, and it's not clear whether we would 
have a vaccine ready to use before this current epidemic ends."
  Chinese
 health authorities announced Wednesday that 440 confirmed cases of 
pneumonia caused by the novel coronavirus had been reported in 13 
provincial-level regions in the country by the end of Tuesday.
  The
 US Centers for Disease Control and Prevention (CDC) announced on 
Tuesday that the first coronavirus case has been reported in the US.
  Infections of the virus have also been reported in the Republic of Korea, Thailand and Japan.
  Hotez said he believes there will be additional cases in the US following the first confirmed case.
  "The
 only good news is that it appears so far that this coronavirus is not 
as transmissible from person to person as was SARS," he said. "But we're
 still early in this epidemic and we have a lot to learn."
  "For 
the long term, we should begin vaccine development and have it ready. 
For now, we need to find ways to protect our healthcare workers who are 
on the front lines," he said.
  Hotez praised China's efforts in 
dealing with the epidemic, saying Chinese scientists have done an 
amazing job so far figuring out the transmission and working out quickly
 the isolation and sequencing of the virus.
  "This is a testament to the power and strength of virology in China," he added.
  However,
 Hotez expressed his concern about person to person spread especially 
since the epidemic is expanding at the start of the Chinese New Year 
when the whole country is on the move.
  "We need to be concerned about travel in the coming days and weeks spreading this virus," he said.
  The
 World Health Organization (WHO) emergency committee convened on 
Wednesday on whether the latest novel coronavirus outbreak in China 
constitutes a Public Health Emergency of International Concern. 
              
                  | 
               
              
                    | 
                         
                     | 
               
              
                |   | 
               
              
                 | 
               
                          
               |  
                | 
               
                          
               | 
                | 
               
              
              | 
               
                | 
               
                          
  |  
               | 
               
              
             | 
           
          | 
        
       
          
             | 
               
          
            | 
          
             | 
           
          
                |   | 
           
         
          
            
              
                |   Customs Exchange Rates | 
                     
              
                | Currency     | 
                      Import      | 
                      Export | 
                     
              
                US Dollar 
  | 
                      ₹88.70
  | 
                      ₹87 | 
                     
              
                UK Pound
  | 
                      ₹119.90
  | 
                      ₹116 | 
                     
              
                Euro
  | 
                      ₹104.25
  | 
                      ₹100.65 | 
                     
              
                | Japanese 
                  Yen | 
                      ₹59.20 | 
                      ₹57.30 | 
                     
              
                | As on 30 Oct, 2025 | 
                     
               
             | 
               
          
             | 
               
          
            
 
    
      |   Daily Poll | 
     
    
      
        
          
              | 
              | 
           
          
            | Who do you think will benefit more from the India - UK FTA in the long run?
 | 
           
         
       | 
     
   
              | 
               
          
             | 
               
          
             | 
               
          
          
             | 
               
          
            
             
            
                 
                  
                    
                      
                        |   Commented Stories  | 
                          | 
                       
                      | 
                   
                  
                     | 
                   
                 
                           | 
               
          
             | 
           
          
          
          
             | 
               
          
            |   | 
             
          
                    |